biostudies-literatureMikasi SGPoliomyelitis Research FoundationSouth African Research Chairs Initiative of the Department of Science and InnovationHigher Education Department, next Generation of ProgrammeSouth African Research Chairs Initiative of the Department of Science and Innovation (DSI)National Research FoundationSouth African Medical Research CouncilDepartment of Science and Technology, Republic of South AfricaHarry Crossley Foundation379https://www.ebi.ac.uk/biostudies/studies/S-EPMC8063366biostudies-literatureUnknown21(1)<h4>Background</h4>The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG containing regimens have shown a high genetic barrier against HIV-1 isolates carrying specific resistance mutations when compared with other class of regimens.<h4>Methods</h4>We evaluated the HIV-1 CRF02_AG IN gene sequences from Cameroon for the presence of resistance-associated mutations (RAMs) against INSTIs and naturally occurring polymorphisms (NOPs), using study sequences (n = 20) and (n = 287) sequences data derived from HIV Los Alamos National Laboratory database. The possible impact of NOPs on protein structure caused by HIV-1 CRF02_AG variations wBMC infectious diseasesInteraction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.PMC806336617/4964751UID: 113547Isaacs DJacobs GBChitongo RMikasi SGCloete RIkomey GMfalseInteraction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.<h4>Background</h4>The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG containing regimens have shown a high genetic barrier against HIV-1 isolates carrying specific resistance mutations when compared with other class of regimens.<h4>Methods</h4>We evaluated the HIV-1 CRF02_AG IN gene sequences from Cameroon for the presence of resistance-associated mutations (RAMs) against INSTIs and naturally occurring polymorphisms (NOPs), using study sequences (n = 20) and (n = 287) sequences data derived from HIV Los Alamos National Laboratory database. The possible impact of NOPs on protein structure caused by HIV-1 CRF02_AG variations w2021-01-01T00:00:00Z2021 Apr2025-04-22T15:49:02.784Z2022-02-09T16:06:33.606ZS-EPMC80633663389262810.1186/s12879-021-06059-x